|
1
|
Mishra S, Bajoria AA, Parihar AS, Kochhar
AS, Bhasin R and Bharadwaj A: Evaluation of lichenoid granulomatous
stomatitis cases: A Retrospective Study. J Nat Rem. 21:55–59.
2020.
|
|
2
|
Vigarios E, Epstein JB and Sibaud V: Oral
mucosal changes induced by anticancer targeted therapies and immune
checkpoint inhibitors. Support Care Cancer. 25:1713–1739.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Motzer RJ, Escudier B, George S, Hammers
HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G,
McDermott DF, et al: Nivolumab versus everolimus in patients with
advanced renal cell carcinoma: Updated results with long-term
follow-up of the randomized, open-label, phase 3 CheckMate 025
trial. Cancer. 126:4156–4167. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dika E, Lambertini M, Gouveia B, Mussi M,
Marcelli E, Campione E, Gurioli C, Melotti B, Alessandrini A and
Ribero S: Oral manifestations in melanoma patients treated with
target or immunomodulatory therapies. J Clin Med.
10(1283)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Enomoto Y, Nakatani H, Kondo S, Kasai T
and Tsuchiya Y: Drug-induced oral lichenoid reaction during
nivolumab therapy. Int J Oral Maxillofac Surg. 48:488–491.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Namiki T, Hanafusa T, Ueno M, Miura K and
Yokozeki H: Severe oral ulcers associated with nivolumab treatment.
JAMA Dermatol. 153:235–237. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Obara K, Masuzawa M and Amoh Y: Oral
lichenoid reaction showing multiple ulcers associated with
anti-programmed death cell receptor-1 treatment: A report of two
cases and published work review. J Dermatol. 45:587–591.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schaberg KB, Novoa RA, Wakelee HA, Kim J,
Cheung C, Srinivas S and Kwong BY: Immunohistochemical analysis of
lichenoid reactions in patients treated with anti-PD-L1 and
anti-PD-1 therapy. J Cutan Pathol. 43:339–346. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Shi VJ, Rodic N, Gettinger S, Leventhal
JS, Neckman JP, Girardi M, Bosenberg M and Choi JN: Clinical and
histologic features of lichenoid mucocutaneous eruptions due to
anti-programmed cell death 1 and anti-programmed cell death ligand
1 immunotherapy. JAMA Dermatol. 152:1128–1136. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
James DG: A clinicopathological
classification of granulomatous disorders. Postgrad Med J.
76:457–465. 2000.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Benn BS, Lombard CM and Krishna G:
Nivolumab-induced granulomatous inflammation of the Pleura. J
Thorac Oncol. 12:e100–e101. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Danlos FX, Pagès C, Baroudjian B,
Vercellino L, Battistella M, Mimoun M, Jebali M, Bagot M, Tazi A
and Lebbé C: Nivolumab-induced sarcoid-like granulomatous reaction
in a patient with advanced melanoma. Chest. 149:e133–e136.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wu J, Kwong BY, Martires KJ, Rieger KE,
Chung WH, Iyer GV and Lacouture ME: Granuloma annulare associated
with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol.
32:e124–e126. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hakeem A, Bhattacharyya I, Aljabri M,
Bindakhil M, Pachigar K, Islam MN, Cohen DM and Fitzpatrick SG:
Lichenoid reaction with granulomatous stomatitis: A retrospective
histologic study of 47 patients. J Oral Pathol Med. 48:846–854.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ferguson A, Golden S and Morrison L:
New-onset oral lichen planus and granulomatous cheilitis in a
66-year-old woman. JAAD Case Rep. 2:177–180. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gonzalez JG, Marcus MD and Cruz DJ: Giant
cell lichenoid dermatitis. J Am Acad Dermatol. 15:87–92.
1986.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Magro CM and Crowson AN: Lichenoid and
granulomatous dermatitis. Int J Dermatol. 39:126–133.
2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Robinson CM, Oxley JD, Weir J and Eveson
JW: Lichenoid and granulomatous stomatitis: An entity or a
non-specific inflammatory process? J Oral Pathol Med. 35:262–267.
2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hofmann L, Forschner A, Loquai C,
Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal
JS, Göppner D, et al: Cutaneous, gastrointestinal, hepatic,
endocrine, and renal side-effects of anti-PD-1 therapy. Eur J
Cancer. 60:190–209. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sibaud V, Eid C, Belum VR, Combemale P,
Barres B, Lamant L, Mourey L, Gomez-Roca C, Estilo CL, Motzer R, et
al: Oral lichenoid reactions associated with anti-PD-1/PD-L1
therapies: Clinicopathological findings. J Eur Acad Dermatol
Venereol. 31:e464–e469. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Diaz-Perez JA, Beveridge MG, Victor TA and
Cibull TL: Granulomatous and lichenoid dermatitis after IgG4
anti-PD-1 monoclonal antibody therapy for advanced cancer. J Cutan
Pathol. 45:434–438. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Khelifa-Hamdani E, Touati-Serraj M,
Perriard J, Chavaz P, Saurat JH and Kaya G: Giant cell lichenoid
dermatitis in a patient with baboon syndrome. J Cutan Pathol. 35
(Suppl 1):S17–S19. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Errico A: Immunotherapy: PD-1-PD-L1 axis:
Efficient checkpoint blockade against cancer. Nat Rev Clin Oncol.
12(63)2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Villadolid J and Amin A: Immune checkpoint
inhibitors in clinical practice: Update on management of
immune-related toxicities. Transl Lung Cancer Res. 4:560–575.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Costa NL, Gonçalves JAM, de Lima SLG, de
Arruda JAA, Miranda ACC, Mesquita RA, da Silveira ÉJD and Batista
AC: Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response
in oral lichen planus. Oral Diseases. 26:1246–1254. 2020.PubMed/NCBI View Article : Google Scholar
|
